PL2215075T3 - Pochodne chinolinonu jako inhibitory PARP - Google Patents

Pochodne chinolinonu jako inhibitory PARP

Info

Publication number
PL2215075T3
PL2215075T3 PL08841176T PL08841176T PL2215075T3 PL 2215075 T3 PL2215075 T3 PL 2215075T3 PL 08841176 T PL08841176 T PL 08841176T PL 08841176 T PL08841176 T PL 08841176T PL 2215075 T3 PL2215075 T3 PL 2215075T3
Authority
PL
Poland
Prior art keywords
parp inhibitors
quinolinone derivatives
quinolinone
derivatives
parp
Prior art date
Application number
PL08841176T
Other languages
English (en)
Polish (pl)
Inventor
Patrick René Angibaud
Laurence Françoise Bernadette Marconnet-Decrane
Jorge Eduardo Vialard
Laurence Anne Mevellec
Christophe Meyer
Pierre-Henri Storck
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PL2215075T3 publication Critical patent/PL2215075T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
PL08841176T 2007-10-26 2008-10-22 Pochodne chinolinonu jako inhibitory PARP PL2215075T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07119417 2007-10-26
EP08841176.4A EP2215075B1 (en) 2007-10-26 2008-10-22 Quinolinone derivatives as parp inhibitors
PCT/EP2008/064243 WO2009053373A1 (en) 2007-10-26 2008-10-22 Quinolinone derivatives as parp inhibitors

Publications (1)

Publication Number Publication Date
PL2215075T3 true PL2215075T3 (pl) 2014-04-30

Family

ID=39345428

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08841176T PL2215075T3 (pl) 2007-10-26 2008-10-22 Pochodne chinolinonu jako inhibitory PARP

Country Status (6)

Country Link
US (1) US8404713B2 (enExample)
EP (1) EP2215075B1 (enExample)
JP (1) JP5525447B2 (enExample)
ES (1) ES2448870T3 (enExample)
PL (1) PL2215075T3 (enExample)
WO (1) WO2009053373A1 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
WO2013169964A1 (en) * 2012-05-09 2013-11-14 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
WO2014085486A2 (en) 2012-11-30 2014-06-05 Waters Technologies Corporation Methods and apparatus for the analysis of vitamin d metabolites
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
JP6563017B2 (ja) 2014-08-28 2019-08-21 エースニューロン・ソシエテ・アノニム グリコシダーゼ阻害剤
PH12017502228B1 (en) * 2015-06-09 2022-08-03 Onconic Therapeutics Inc Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
EP3419976B1 (en) 2016-02-25 2021-04-07 Asceneuron SA Acid addition salts of piperazine derivatives
CA3012560A1 (en) 2016-02-25 2017-08-31 Asceneuron S.A. Glycosidase inhibitors
CA3012624A1 (en) 2016-02-25 2017-08-31 Asceneuron S.A. Glycosidase inhibitors
MX2019010085A (es) 2017-02-24 2019-11-21 Asceneuron S A Inhibidores de la glicosidasa de sulfoximina.
WO2019037860A1 (en) 2017-08-24 2019-02-28 Asceneuron S.A. LINEAR INHIBITORS OF GLYCOSIDASE
US11458140B2 (en) 2017-08-24 2022-10-04 Asceneuron Sa Annulated glycosidase inhibitors
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors
US11731972B2 (en) 2018-08-22 2023-08-22 Asceneuron Sa Spiro compounds as glycosidase inhibitors
KR102839500B1 (ko) 2018-08-22 2025-07-28 아셰뉴론 에스아 글리코시다제 억제제로서 유용한 피페라진 유도체의 숙시네이트 및 푸마레이트 산 부가염
WO2020039028A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Tetrahydro-benzoazepine glycosidase inhibitors
US20220143042A1 (en) 2019-02-22 2022-05-12 Asceneuron Sa Fused glycosidase inhibitors
CN114144413B (zh) * 2019-07-19 2024-08-16 阿斯利康(瑞典)有限公司 Parp1抑制剂
CA3148767A1 (en) * 2019-07-26 2021-02-04 Health Research, Inc. Treatment of p53-deficient cancers
US11795158B2 (en) * 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
EP4326713A4 (en) * 2021-04-12 2025-03-19 Impact Therapeutics (Shanghai), Inc. Substituted fused bicyclic compounds as parp inhibitors and the use thereof
WO2022225934A1 (en) 2021-04-19 2022-10-27 Xinthera, Inc. Parp1 inhibitors and uses thereof
CA3213029A1 (en) * 2021-04-22 2022-10-27 Yuli Xie Parp inhibitor containing piperazine structure, preparation method therefor and pharmaceutical use thereof
CN115232154A (zh) * 2021-04-23 2022-10-25 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
TW202304911A (zh) * 2021-04-23 2023-02-01 大陸商南京明德新藥研發有限公司 吡啶醯胺類化合物
CN116710433A (zh) * 2021-04-23 2023-09-05 成都百裕制药股份有限公司 一种选择性parp1抑制剂及其应用
WO2022222964A1 (zh) * 2021-04-23 2022-10-27 成都百裕制药股份有限公司 吡啶衍生物及其在医药上的应用
MX2023013890A (es) 2021-05-24 2023-12-11 Jiangsu Hengrui Pharmaceuticals Co Ltd Compuesto heterociclico que contiene nitrogeno, metodo de preparacion del mismo y aplicacion del mismo en medicamentos.
WO2023036285A1 (zh) * 2021-09-09 2023-03-16 南京奥利墨斯医药科技有限公司 一种杂芳环类化合物及其应用
WO2023046034A1 (zh) * 2021-09-22 2023-03-30 明慧医药（杭州）有限公司 一种含氮杂环化合物、其制备方法、其中间体及其应用
WO2023046149A1 (zh) * 2021-09-26 2023-03-30 张文燕 喹喔啉类化合物及其医药用途
WO2023051716A1 (zh) * 2021-09-30 2023-04-06 海思科医药集团股份有限公司 杂芳基衍生物parp抑制剂及其用途
US20240391937A1 (en) * 2021-09-30 2024-11-28 Xizang Haisco Pharmaceutical Co., Ltd. Bicyclic derivative parp inhibitor and use thereof
CN118043322A (zh) * 2021-09-30 2024-05-14 西藏海思科制药有限公司 含氮杂环衍生物parp抑制剂及其用途
PE20241129A1 (es) * 2021-10-01 2024-05-24 Xinthera Inc Inhibidores de parp1 de azetidina y pirrolidina y usos de estos
US20250222116A1 (en) * 2021-10-22 2025-07-10 Xizang Haisco Pharmaceutical Co., Ltd. Parp-1 degradation agent and use thereof
MX2024006074A (es) * 2021-11-19 2024-06-28 Kangbaida Sichuan Biotechnology Co Ltd Inhibidor de parp1 selectivo y aplicacion del mismo.
KR20240144125A (ko) * 2021-12-17 2024-10-02 키테라 (쑤저우) 바이오-파마슈티컬스 컴퍼니 리미티드 Parp 억제제, 이를 포함하는 약제학적 조성물, 및 이의 용도
CN118434725A (zh) * 2022-01-20 2024-08-02 微境生物医药科技(上海)有限公司 吡啶酰胺类parp抑制剂、及其制备方法和医药用途
CN118804916B (zh) 2022-01-21 2025-04-01 新特拉有限公司 Parp1抑制剂及其用途
KR20240139604A (ko) * 2022-01-27 2024-09-23 신테라, 인크. Parp1 저해제 및 이의 용도
AU2023212785A1 (en) * 2022-01-28 2024-08-15 Xinthera, Inc. Parp1 inhibitors and uses thereof
EP4493551A1 (en) 2022-03-14 2025-01-22 Slap Pharmaceuticals LLC Multicyclic compounds
WO2023207284A1 (en) * 2022-04-28 2023-11-02 Ningbo Newbay Technology Development Co., Ltd Piperazine derivatives as parp1 inhibitiors
IL316278A (en) 2022-04-28 2024-12-01 Xinthera Inc TRICYCLIC PARP1 INHIBITORS AND THEIR USES
CN119487027A (zh) * 2022-04-28 2025-02-18 宁波新湾科技发展有限公司 作为parp1抑制剂的化合物
WO2023227052A1 (zh) * 2022-05-25 2023-11-30 西藏海思科制药有限公司 双环衍生物parp抑制剂及其用途
CN119677736A (zh) * 2022-08-24 2025-03-21 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂药学上可接受的盐及其用途
WO2024041608A1 (zh) * 2022-08-24 2024-02-29 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂的晶体形式及其用途
CN117658983A (zh) * 2022-09-01 2024-03-08 浙江文达医药科技有限公司 选择性parp1抑制剂
CN120112531A (zh) * 2022-10-20 2025-06-06 成都赜灵生物医药科技有限公司 并杂环类化合物及其用途
CN120019054A (zh) * 2022-10-20 2025-05-16 成都赜灵生物医药科技有限公司 取代四氢吡啶类化合物及其用途
IL320998A (en) 2022-11-23 2025-07-01 Jiangsu Hengrui Pharmaceuticals Co Ltd A pharmaceutically acceptable salt of a nitrogen-containing heterocyclic compound, its crystalline form and a method for preparing them
KR20250117449A (ko) * 2022-12-23 2025-08-04 제지앙 양리 파마슈티칼 테크놀로지 씨오., 엘티디. Parp1 억제제
CN117903159A (zh) * 2022-12-30 2024-04-19 成都硕德药业有限公司 一种内酰胺类衍生物、其制备方法及用途
WO2025101892A1 (en) * 2023-11-10 2025-05-15 Astellas Engineered Small Molecules US, Incorporated Poly-adp ribose polymerase (parp) inhibitors and uses thereof
CN120040415A (zh) * 2023-11-24 2025-05-27 中国药科大学 一种含喹啉酮骨架的化合物及其应用
WO2025168048A1 (zh) * 2024-02-08 2025-08-14 上海璎黎药业有限公司 一种三键结构化合物、其药物组合物及其应用

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB732581A (en) 1952-01-18 1955-06-29 Ciba Ltd Manufacture of hydrazine compounds
DE1006423B (de) 1952-01-18 1957-04-18 Ciba Geigy Verfahren zur Herstellung von Hydrazinophthalazinen
US3274194A (en) * 1963-03-29 1966-09-20 Miles Lab Quinazolinedione derivatives
GB1062357A (en) 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
US3919425A (en) * 1971-04-09 1975-11-11 Miles Lab Method of producing vasodilation using certain 3-substituted-quinazoline derivatives
BE792206A (enExample) 1971-12-02 1973-06-01 Byk Gulden Lomberg Chem Fab
FR2436781A1 (fr) 1978-09-19 1980-04-18 Berri Balzac Derives d'amino-3 (1h,3h) quinazolinedione-2,4, leur procede de preparation et leurs applications en therapeutique
US4335127A (en) * 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
JPS5976082A (ja) 1982-10-23 1984-04-28 Kyowa Hakko Kogyo Co Ltd 新規なピペリジン誘導体
JPS60120872A (ja) 1983-12-01 1985-06-28 Kyowa Hakko Kogyo Co Ltd 新規なヘテロ環状化合物及び強心剤
PL147465B1 (en) 1984-03-26 1989-06-30 Janssen Pharmaceutica Nv Method of obtaining novel pyridazionoamine compounds
US5001125A (en) 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
US5231184A (en) * 1987-11-23 1993-07-27 Janssen Pharmaceutica N.V. Pridazinamine derivatives
US5177075A (en) * 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
CA2002864C (en) 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
GB8827822D0 (en) * 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
EP0391462A1 (en) 1989-04-05 1990-10-10 Janssen Pharmaceutica N.V. Synergistic compositions containing ketanserin
US5160727A (en) 1990-02-13 1992-11-03 Warner-Lambert Company Tumor cell sensitization method using quinazolinedione derivatives
IE913473A1 (en) * 1990-10-15 1992-04-22 Fujisawa Pharmaceutical Co Quinazoline derivatives and their preparation
EP0637306B1 (en) 1992-04-23 2001-05-30 Merrell Pharmaceuticals Inc. 4-imidomethyl-1- [2'-phenyl-2'-oxoethyl]- piperidines as serotonin 5ht 2-antagonists, their preparation and use in therapy
TW294595B (enExample) 1992-11-20 1997-01-01 Janssen Pharmaceutica Nv
EP0638567A4 (en) 1993-02-18 1995-05-10 Kyowa Hakko Kogyo Kk ADENOSINE INHIBITORS.
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
TW445263B (en) 1996-02-29 2001-07-11 Janssen Pharmaceutica Nv Novel esters of 1,4-disubstituted piperidine derivatives
JPH107572A (ja) 1996-06-17 1998-01-13 Sumitomo Pharmaceut Co Ltd 腫瘍壊死因子産生阻害剤
ES2314305T3 (es) 1996-09-10 2009-03-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Aminoacidos modificados, medicamentos que contienen estos compuestos y procedimiento para su obtencion.
EP0999208A4 (en) * 1997-05-30 2001-08-08 Meiji Seika Kaisha NITROGEN-BASED HETEROCYCLIC COMPOUNDS AND MEDICINES FOR TREATING HYPERLIPEMIA THAT CONTAIN THEM
JPH10330377A (ja) 1997-06-02 1998-12-15 Kyowa Hakko Kogyo Co Ltd ピペリジン誘導体
US6635642B1 (en) * 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US20020022636A1 (en) * 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
CA2302453A1 (en) 1997-09-16 1999-03-25 Atsuhiro Inaba Nitrogenous fused-ring compounds, process for the preparation of the same, and drugs
US6133277A (en) 1997-12-05 2000-10-17 Janssen Pharmaceutica N.V. (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties
JP2000191659A (ja) 1999-01-04 2000-07-11 Sumitomo Pharmaceut Co Ltd 腫瘍壊死因子産生阻害剤
ES2209825T3 (es) 1999-01-29 2004-07-01 Abbott Laboratories Derivados diazabiciclicos utiles como ligandos del receptor nicotinico de la acetilcolina.
US7265115B2 (en) * 1999-01-29 2007-09-04 Abbott Laboratories Diazabicyclic CNS active agents
US6566372B1 (en) * 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
AU9384701A (en) 2000-10-02 2002-04-15 Janssen Pharmaceutica Nv Metabotropic glutamate receptor antagonists
ITMI20002358A1 (it) 2000-10-31 2002-05-01 Flavio Moroni Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi
AUPR201600A0 (en) * 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
JP2002284699A (ja) 2001-03-28 2002-10-03 Sumitomo Pharmaceut Co Ltd 視細胞変性疾患治療剤
EP1396488A1 (en) * 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
EP1423120A4 (en) 2001-08-15 2005-12-28 Icos Corp 2H-PHTALAZINE-1-ONES AND METHODS OF USE THEREOF
WO2003039460A2 (en) 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors
AUPR975601A0 (en) 2001-12-24 2002-01-31 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivatives
US6822097B1 (en) * 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
JP4573533B2 (ja) 2002-03-29 2010-11-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 放射能標識付きキノリンおよびキノリノン誘導体および代謝向性グルタメート受容体リガンドとしてのそれらの使用
US7119111B2 (en) 2002-05-29 2006-10-10 Amgen, Inc. 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
WO2004048339A1 (ja) * 2002-11-22 2004-06-10 Mitsubishi Pharma Corporation イソキノリン化合物及びその医薬用途
US20050075364A1 (en) 2003-07-01 2005-04-07 Kap-Sun Yeung Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
ES2670349T3 (es) * 2003-11-20 2018-05-30 Janssen Pharmaceutica Nv 2-Quinolinonas y 2-quinoxalinonas sustituidas con 6-alquenilo y 6-fenilalquilo como inhibidores de poli(ADP-ribosa) polimerasa
MXPA06005686A (es) * 2003-11-20 2006-08-17 Janssen Pharmaceutica Nv 2-quinolinonas y 2-quinoxalinonas 7-fenilaquilo sustituidas como inhibidores de la poli(adp-ribosa)polimerasa.
KR101118582B1 (ko) 2003-11-20 2012-02-27 얀센 파마슈티카 엔.브이. 폴리(ａｄｐ-리보스)폴리머라제 저해제로서의 6-알케닐 및6-페닐알킬 치환된 2-퀴놀리논 및 2-퀴녹살리논
JP4772690B2 (ja) 2003-12-03 2011-09-14 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド チューブリン阻害剤
CA2546657C (en) 2003-12-05 2013-05-14 Janssen Pharmaceutica N.V. 6-substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
JP4948178B2 (ja) * 2003-12-10 2012-06-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤としての置換６−シクロヘキシルアルキル置換２−キノリノンおよび２−キノキサリノン
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
JP4991527B2 (ja) 2004-06-01 2012-08-01 ユニバーシティ オブ バージニア パテント ファンデーション 二つの部分からなる低分子量の癌および血管新生の抑制剤
CN1980674B (zh) 2004-06-30 2011-05-25 詹森药业有限公司 作为parp抑制剂的2,3-二氮杂萘衍生物
EA012837B1 (ru) 2004-06-30 2009-12-30 Янссен Фармацевтика Н.В. Производные хиназолинона в качестве ингибиторов parp
ES2415771T3 (es) * 2004-06-30 2013-07-26 Janssen Pharmaceutica N.V. Derivados de quinazolina como inhibidores de PARP
EP1919882A2 (en) 2005-02-17 2008-05-14 Synta Pharmaceuticals Corporation Isoxazole combretastatin derivatives for the treatment of proliferative disorders
ES2545382T3 (es) * 2005-04-28 2015-09-10 Mitsubishi Tanabe Pharma Corporation Derivado de cianopiridina y su uso como medicamento
KR20080039508A (ko) 2005-08-24 2008-05-07 이노텍 파마슈티컬스 코포레이션 인데노이소퀴놀리논 유사체 및 이의 사용 방법
ATE555091T1 (de) 2006-02-03 2012-05-15 Bionomics Ltd Substituierte benzofurane, benzothiophene, benzoselenophene und indole und ihre verwendung als tubulinpolymerisationsinhibitoren
BRPI0707902A2 (pt) 2006-02-15 2011-05-17 Abbott Lab pirazoloquinolonas são potentes inibidores parp
US8466150B2 (en) * 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
ATE542799T1 (de) 2007-03-08 2012-02-15 Janssen Pharmaceutica Nv Chinolinonderivate als parp und tank-inhibitoren
CA2690378A1 (en) * 2007-06-25 2008-12-31 Amgen Inc. Phthalazine compounds, compositions and methods of use

Also Published As

Publication number Publication date
WO2009053373A1 (en) 2009-04-30
JP5525447B2 (ja) 2014-06-18
EP2215075A1 (en) 2010-08-11
EP2215075B1 (en) 2013-12-11
US8404713B2 (en) 2013-03-26
US20100222348A1 (en) 2010-09-02
ES2448870T3 (es) 2014-03-17
JP2011500758A (ja) 2011-01-06

Similar Documents

Publication Publication Date Title
PL2215075T3 (pl) Pochodne chinolinonu jako inhibitory PARP
IL205142A0 (en) Pyridazinone derivatives as parp inhibitors
IL208103A0 (en) Quinoline derivatives as axl kinase inhibitors
IL193265A0 (en) Quinoline derivatives
IL202018A0 (en) Quinoline derivatives as pi3 kinase inhibitors
EP2194044A4 (en) QUINOLONE DERIVATIVE
IL200656A0 (en) Quinoline derivatives as fungicides
ZA201005166B (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
ZA200806646B (en) Pyrazoloquinolones are potent parp inhibitors
ZA201006475B (en) Heterocyclic derivatives
IL212755A0 (en) Pyrazinopyrazines and derivatives as kinase inhibitors
IL212842A0 (en) Azaindole derivatives as kinase inhibitors
ZA201007317B (en) Tertiary amine derivatives as phosphodiesterase-4 inhibitors
ZA201005382B (en) Substituted heteroarylamide diazepinopyrimidone derivatives
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
ZA201007431B (en) Imidazolidinone derivatives as 11b-hsd1 inhibitors
ZA201005381B (en) Substituted heteroarylamide oxazepinopyrimidone derivatives
ZA200906423B (en) Pyrazolone derivatives as PDE4 inhibitors
IL206949A0 (en) 2-aminoquinoline derivatives
EP2344472A4 (en) ISOCHINOLINONDERIVATE
GB0714941D0 (en) Inhibitors
ZA200806877B (en) Quinoline Derivatives
GB0713152D0 (en) Phosphodlesterase inhibitors
HK1158642A (en) Isoquinolinone derivatives
GB0621107D0 (en) Inhibitors of phosphodiesterase-4